EN DE
STOCK COMPARISON

Shandong Weigao Blood vs Abbott Laboratories: Fair Value & Quality

Both stocks run through our valuation models. Here is how Shandong Weigao Blood (603014) and Abbott Laboratories (ABT) compare, as of Sep 24, 2026.

As of Sep 24, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Shandong Weigao Blood trades at ¥31.58 versus a fair value of ¥18.56 (-41%), while Abbott Laboratories trades at $103 versus $74.79 (-28%).
Shandong Weigao Blood
603014.SHG · CNY · Health Care
-41%
upside to fair value
overvalued
Price¥31.58
Fair Value¥18.56
Quality51/100
Abbott Laboratories
ABT · USD · Health Care
-28%
upside to fair value
overvalued
Price$103
Fair Value$74.79
Quality66/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

Shandong Weigao BloodAbbott Laboratories
Valuation
26.3×P/E (TTM)28.5×
3.78×P/S (TTM)4.01×
2.01×P/B3.47×
16.0×EV/EBITDA15.5×
n/aPEG1.47×
−41.2%Fair value upside−27.7%
1.6%Dividend yield2.4%
¥0.52Dividend per share$2.44
Profitability
15%Operating margin13%
1.23×EBIT margin trend (5Y)1.19×
8%Return on equity12%
4%Return on assets6%
Growth
1%Revenue growth (YoY)8%
3.2%Avg. growth/yr (3Y)0.5%
n/aAvg. growth/yr (5Y)5.1%
+10.8%Value creation/yr+10.6%
Balance & size
749.6×Interest coverage (EBIT/interest)23.6×
n/aDebt / equity0.19×
$2BMarket cap$181B
healthyGrowth qualityhealthy

Shandong Weigao Blood leads: 8 to 4 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Shandong Weigao Bloodof which business quality 55 · market factors 31 Abbott Laboratoriesof which business quality 66 · market factors 50
ProfitabilityMargins and returns on capital today
39
50
Quality GrowthAre margins and returns improving?
29
47
CashflowEarnings quality: real cash, not paper profit
75
71
Fin. StrengthBalance sheet, leverage, solvency risk
92
80
InvestmentDisciplined investing over empire-building
53
65
Low VolatilityCalm price path (market factor)
56
83
MomentumPrice trend over the last 3–12 months (market factor)
26
43
52W MomentumDistance to the 52-week high (market factor)
10
25
Net IssuanceShare count: buybacks or dilution?
20
84

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyShandong Weigao BloodPrice ¥31.58Abbott LaboratoriesPrice $103
DCF Models-13%close to the price¥27.57-28%below the price$74.80
Earnings-Based-51%below the price¥15.50-72%below the price$29.42
Dividend Discount-92%below the price¥2.40-62%below the price$39.73
Multiples-26%below the price¥23.27-32%below the price$70.72
Asset-Based-64%below the price¥11.42-81%below the price$20.05
Growth DCF-19%below the price¥25.44-34%below the price$68.58
Economic Profit-53%below the price¥14.89-64%below the price$37.49
Growth Earnings-34%below the price¥20.74-32%below the price$70.25
Minimum-92%below the price¥2.40-81%below the price$20.05
Maximum-13%close to the price¥27.57-28%below the price$74.80
Median-43%below the price¥18.12-48%below the price$54.15
Geometric mean-54%below the price¥14.66-55%below the price$46.64

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Shandong Weigao Blood: 25 of 25 models see the stock below the current price.

Abbott Laboratories: 26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Shandong Weigao Blood
Price ¥31.58
Fair Value ¥18.56
Bear ¥13.75Bull ¥23.38
Abbott Laboratories
Price $103
Fair Value $74.79
Bear $52.12Bull $94.43

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Shandong Weigao Blood · Health Care

Quality score51 · above median
Fair value upside-41% · below median

Abbott Laboratories · Health Care

Quality score66 · Top 25%
Fair value upside-28% · below median

Bottom line

As of Sep 24, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Shandong Weigao Blood trades at ¥31.58 versus a fair value of ¥18.56 (-41%), while Abbott Laboratories trades at $103 versus $74.79 (-28%).

Abbott Laboratories has the higher quality score (66/100).

Open Abbott Laboratories live analysis →
Shandong Weigao Blood · Abbott Laboratories

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Shandong Weigao Blood

Microsoft vs NvidiaApple vs MicrosoftNvidia vs Taiwan Semiconductor ManufacturingApple vs Taiwan Semiconductor Manufacturing

Related to Abbott Laboratories

Alphabet Inc Class C vs Meta PlatformsCisco Systems vs NvidiaMicrosoft vs Taiwan Semiconductor ManufacturingApple vs Cisco Systems
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.